Adamantan-2-yl-urea | 41031-27-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: Adamantan-2-yl-urea
• 英文别名: (Adamantan-2-yl)urea；2-adamantylurea
• CAS: 41031-27-0
• 化学式: C₁₁H₁₈N₂O
• mdl: MFCD00074734
• 分子量: 194.277
• InChiKey: LQXUPNMWDYTSKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  ethyl 1-(2-(aminomethyl)benzyl)-1H-pyrrole-2-carboxylate 、 Adamantan-2-yl-urea 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以59.3%的产率得到ethyl 1-(2-((3-((3s,5s,7s)-adamantan-1-yl)ureido)methyl)benzyl)-1H-pyrrole-2-carboxylate
  参考文献：
  名称：

  Design and Synthesis of Dual Modulators of Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptors

  摘要：

  Metabolic syndrome is a complex condition which often requires the use of multiple medications as a treatment. The resulting problems of polypharmacy are increase in side effects, drug-drug interactions, and its high economic cost. Development of multitarget compounds is a promising strategy to avoid the complications arising from administration of multiple drugs. Modulators of peroxisome proliferator-activated receptors (PPARs) are established agents in the treatment of dyslipidaemia, hyperglycaemia, and insulin resistance. Inhibitors of soluble epoxide hydrolase (sEH) are under evaluation for their use in cardiovascular diseases. In the present study, a series of dual sEH/PPAR modulators containing a pyrrole acidic headgroup and a urea pharmacophore were designed, synthesized, and evaluated in vitro using recombinant enzyme and cell-based assays. Compounds with different activity profiles were obtained which could be used in the treatment of metabolic syndrome.

  DOI：

  10.1021/jm301194c

文献信息

• USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS
  申请人：Webb Hsu Heather K.

  公开号：US20090270452A1

  公开（公告）日：2009-10-29

  Disclosed herein are compounds, compositions, and methods for enhancing smooth muscle function in a subject by administration of soluble epoxide hydrolase inhibitors and for treating subjects with smooth muscle disorders including erectile dysfunction, overactive bladder, uterine contractions and irritable bowel syndrome.

  本文揭示了一种通过给予可溶性环氧化物水解酶抑制剂来增强受试者平滑肌功能的化合物、组合物和方法，并用于治疗患有平滑肌障碍的受试者，包括勃起功能障碍、膀胱过度活跃、子宫收缩和肠易激综合征。
• 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
  申请人：Merck Sante

  公开号：EP1801098A1

  公开（公告）日：2007-06-27

  The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.

  本发明涉及公式I的2-金刚烷基脲衍生物，作为选择性抑制酶11-β-羟基类固醇脱氢酶1（11β-HSD1）的药物，并利用这些化合物治疗和预防代谢综合征、糖尿病、胰岛素抵抗、肥胖、脂质紊乱、青光眼、骨质疏松症、认知障碍、焦虑、抑郁、免疫紊乱、高血压以及其他疾病和症状。
• SOLUBLE EPOXIDE HYDROLASE INHIBITORS
  申请人：Gless Richard D.

  公开号：US20080227780A1

  公开（公告）日：2008-09-18

  Disclosed are urea compounds, stereoisomer, or pharmaceutical acceptable salt thereof, and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetic-related diseases.

  本公开涉及尿素化合物、其立体异构体或药用可接受的盐，以及抑制可溶性环氧化物水解酶（sEH）的组合物，制备这些化合物和组合物的方法，以及使用这些化合物和组合物治疗患者的方法。这些化合物、组合物和方法可用于治疗多种由sEH介导的疾病，包括高血压、心血管、炎症、肺部和糖尿病相关疾病。
• Process for the preparation of memantine and its hydrochloric acid salt form
  申请人：KRKA

  公开号：EP1908748A1

  公开（公告）日：2008-04-09

  The present invention relates to the synthesis of 1-amino-3,5-dimethyladamantane ("memantine") and its hydrochloric acid salt form. In particular a new intermediate (N-chloro-acetylamino-3,5-dimethyladamantane) for the synthesis of memantine as well as a new process for the preparation of memantine and its hydrochloric acid salt form using said intermediate is disclosed.

  本发明涉及合成1-氨基-3,5-二甲基金刚烷（“美金刚烷”）及其盐酸盐形式。具体地，本发明揭示了用于合成美金刚烷的新中间体（N-氯乙酰氨基-3,5-二甲基金刚烷）以及使用该中间体制备美金刚烷及其盐酸盐形式的新工艺。
• Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
  申请人：Merli Valeriano

  公开号：US20060173215A1

  公开（公告）日：2006-08-03

  A process for the preparation of memantine hydrochloride, intermediates thereof and its hydrochloric acid form are provided.

  提供了一种制备美金刚烷盐酸盐、其中间体及其盐酸形式的过程。